HRP20100356T1 - Diagnostic marker for cancer - Google Patents

Diagnostic marker for cancer Download PDF

Info

Publication number
HRP20100356T1
HRP20100356T1 HR20100356T HRP20100356T HRP20100356T1 HR P20100356 T1 HRP20100356 T1 HR P20100356T1 HR 20100356 T HR20100356 T HR 20100356T HR P20100356 T HRP20100356 T HR P20100356T HR P20100356 T1 HRP20100356 T1 HR P20100356T1
Authority
HR
Croatia
Prior art keywords
protein
regulated
minor changes
annexin
minor
Prior art date
Application number
HR20100356T
Other languages
Croatian (hr)
Inventor
Cahill Michael
Klocker Helmut
Rogatsch Hermann
Original Assignee
Proteosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2005/001567 external-priority patent/WO2005078124A2/en
Application filed by Proteosys Ag filed Critical Proteosys Ag
Publication of HRP20100356T1 publication Critical patent/HRP20100356T1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Use of the protein annexin A3 (I) as a diagnostic marker for prostatic cancer (PC), is new. Independent claims are also included for the following: (1) use of mitochondrial enoyl-coenzyme A-hydratase (III), ubiquitin-isopeptidase T (IV) and/or protein disulfide isomerase (V), serum amyloid P-component (VI), HES1 (VIII), the proteosome alpha -2 subunit (IX) or both (IV) and VI) as diagnostic markers for cancer; (2) use of nuclear chloride ion channel protein (VIII), adenine-phosphoribosyl transferase (X) and inorganic pyrophosphatase (XI) as diagnostic markers for PC; (3) use of a combination of the specified proteins as markers for cancer; (4) diagnostic kit that includes at least one substance for determining activity and/or abundance of the specified proteins; (5) use of an agent (II) that interacts with one of the specified marker proteins to modify its activity and/or abundance, to prepare a composition for treating (prostatic) cancer; and (6) screning for (II) that uses at least one of (I), (IV), (VI), (VII), 14-3-3 protein tau, (III), (VIII), (IX), (X), (XI) and/or their dervatives. ACTIVITY : Cytostatic; Osteopathic; Antiarthritic; Antiarteriosclerotic. No biological data is given. MECHANISM OF ACTION : Regulating activity and/or expression of marker proteins.

Claims (3)

1. Uporaba proteina aneksin A3 kao dijagnostičkog pokazatelja (markera) raka prostate, naznačena time što se pod rakom prostate misli na određene podtipove raka prostate koji se izabiru između sljedećih: podtip a, naznačen pozitivno reguliranim transgelinom, izrazito negativno reguliranim galektinom, izrazito negativno reguliranim mikroseminoproteinom beta, negativno reguliranim proteinom 3 koji veže masne kiseline, bez ili s manjim promjenama proteina koji veže epidermalne masne kiseline, bez ili s manjim promjenama proteina nuklearnog ionskog kloridnog kanala, bez ili s manjim promjenama 14-3-3 proteina beta, bez ili s manjim promjenama 14-3-3 proteina zeta, bez ili s manjim promjenama 14-3-3 proteina tau, bez ili s manjim promjenama aldolaze A, bez ili s manjim promjenama serumske amiloidne P komponente, bez ili s manjim promjenama trioza fosfat izomeraze i/ili bez ili s manjim promjenama aneksina A3, podtip b, naznačen izrazito pozitivno reguliranim proteinom disulfid izomerazom, izrazito pozitivno reguliranim proteinom toplinskog šoka 90, izrazito negativno reguliranom ubikvitin izopeptidazom T, pozitivno reguliranim 14-3-3 proteinom beta, pozitivno reguliranim 14-3-3 proteinom zeta, pozitivno reguliranim14-3-3 proteinom tau, pozitivno reguliranom aldolazom A, pozitivno reguliranom trioza fosfat izomerazom, pozitivno reguliranim aneksinom A3, negativno reguliranim transgelinom, negativno reguliranim galektinom, negativno reguliranim mikroseminoproteinom beta, negativno reguliranom serumskom amiloidnom P komponentom, bez ili s manjim promjenama proteina 3 koji veže masne kiseline i/ili bez ili s manjim promjenama proteina nuklearnog ionskog kloridnog kanala ili podtip c, naznačen izrazito pozitivno reguliranim proteinom nuklearnog ionskog kloridnog kanala, negativno reguliranom serumskom amiloidnom P komponentom, bez ili s manjim promjenama proteina 3 koji veže masne kiseline, bez ili s manjim promjenama 14-3-3 proteina beta, bez ili s manjim promjenama 14-3-3 proteina zeta, bez ili s manjim promjenama 14-3-3 proteina tau, bez ili s manjim promjenama aldolaze A, bez ili s manjim promjenama trioza fosfat izomeraze, s manjim promjenama aneksina A3, bez ili s manjim promjenama proteina koji veže epidermalne masne kiseline, bez ili s manjim promjenama mikroseminoproteina beta, bez ili s manjim promjenama galektina i/ili bez ili s manjim promjenama transgelina.1. The use of annexin A3 protein as a diagnostic indicator (marker) of prostate cancer, indicated by the fact that prostate cancer refers to certain subtypes of prostate cancer that are chosen from among the following: subtype a, indicated by up-regulated transgelin, highly down-regulated galectin, highly down-regulated microseminoprotein beta, down-regulated fatty acid-binding protein 3, no or minor changes in epidermal fatty acid-binding protein, no or minor changes in nuclear chloride ion channel protein , without or with minor changes in 14-3-3 protein beta, without or with minor changes in 14-3-3 protein zeta, without or with minor changes in 14-3-3 protein tau, without or with minor changes in aldolase A, without or with minor changes in the serum amyloid P component, without or with minor changes in triose phosphate isomerase and/or without or with minor changes in annexin A3, subtype b, indicated by strongly positive regulated protein disulfide isomerase, strongly positively regulated heat shock protein 90, strongly negatively regulated ubiquitin isopeptidase T, positively regulated 14-3-3 protein beta, positively regulated 14-3-3 protein zeta, positively regulated 14-3 -3 protein tau, up-regulated aldolase A, up-regulated triose phosphate isomerase, up-regulated annexin A3, down-regulated transgelin, down-regulated galectin, down-regulated microseminoprotein beta, down-regulated serum amyloid P component, without or with minor changes in binding protein 3 fatty acids and/or without or with minor alterations of the nuclear ion chloride channel protein or subtype c, indicated by highly up-regulated nuclear chloride ion channel protein, down-regulated serum amyloid P component, no or minor changes in fatty acid-binding protein 3, no or minor changes in 14-3-3 protein beta, no or minor changes 14-3-3 protein zeta, without or with minor changes 14-3-3 protein tau, without or with minor changes aldolase A, without or with minor changes triose phosphate isomerase, with minor changes annexin A3, without or with minor protein changes which binds epidermal fatty acids, with no or minor changes in microseminoprotein beta, no or minor changes in galectins and/or no or minor changes in transgelin. 2. Uporaba prema zahtjevu 1, naznačena time što se ispituje pozitivna regulacija aneksina A3 u usporedbi s kontrolama.2. Use according to claim 1, characterized in that positive regulation of annexin A3 is tested in comparison with controls. 3. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time što se ispituje pozitivna regulacija aneksina A3 u kombinaciji s negativnom regulacijom aneksina A1, aneksina A2 i/ili aneksina A5.3. Use according to any of the preceding claims, indicated by examining the positive regulation of annexin A3 in combination with the negative regulation of annexin A1, annexin A2 and/or annexin A5.
HR20100356T 2004-02-16 2010-06-28 Diagnostic marker for cancer HRP20100356T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004008449 2004-02-16
DE102004038076A DE102004038076A1 (en) 2004-02-16 2004-07-29 Use of annexin A3, or other proteins, as diagnostic markers for cancer, especially of the prostate, also use of modulators of these markers for treating cancer
PCT/EP2005/001567 WO2005078124A2 (en) 2004-02-16 2005-02-16 Diagnostic marker for cancer

Publications (1)

Publication Number Publication Date
HRP20100356T1 true HRP20100356T1 (en) 2010-09-30

Family

ID=34813531

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100356T HRP20100356T1 (en) 2004-02-16 2010-06-28 Diagnostic marker for cancer

Country Status (9)

Country Link
CN (1) CN101027099B (en)
AT (1) ATE468158T1 (en)
DE (2) DE102004038076A1 (en)
DK (1) DK1720611T3 (en)
ES (1) ES2345392T3 (en)
HR (1) HRP20100356T1 (en)
PT (1) PT1720611E (en)
RS (1) RS51391B (en)
SI (1) SI1720611T1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009234930B2 (en) * 2008-04-08 2011-11-17 Kinki University Method of discriminating bovine, thus discriminated bovine and kit for discriminating bovine
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
WO2013037118A1 (en) * 2011-09-16 2013-03-21 上海长海医院 Prostate cancer biomarkers, therapeutic targets and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000993D0 (en) * 2000-01-18 2000-03-08 Univ Nottingham Trent Cancer associated genes and their products
AU2001244341A1 (en) * 2000-04-01 2001-10-15 Onyvax Limited New prostate cell lines
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Also Published As

Publication number Publication date
CN101027099A (en) 2007-08-29
RS51391B (en) 2011-02-28
DE102004038076A1 (en) 2005-09-01
DE502005009597D1 (en) 2010-07-01
ATE468158T1 (en) 2010-06-15
CN101027099B (en) 2013-04-03
SI1720611T1 (en) 2010-09-30
ES2345392T3 (en) 2010-09-22
PT1720611E (en) 2010-08-26
DK1720611T3 (en) 2010-09-06

Similar Documents

Publication Publication Date Title
Deshpande et al. Primary structure and phosphorylation of dentin matrix protein 1 (DMP1) and dentin phosphophoryn (DPP) uniquely determine their role in biomineralization.
Becquart et al. Human mesenchymal stem cell responses to hydrostatic pressure and shear stress
Rabenold et al. Scratching the surface: a critique of Lucas et al.(2013)'s conclusion that phytoliths do not abrade enamel
CL2011000010A1 (en) Monoclonal anti-beta-amyloid peptide antibody; polynucleotide that encodes it; hybridoma; Method of production; composition comprising it; use to treat diseases related to amyloid proteins; method of diagnosing them; and kit that includes it.
BRPI0411552A (en) sclerostin-specific antibodies and methods to increase bone mineralization
BRPI0710928B8 (en) skin plaster and manufacturing methods for this
CR10181A (en) ANTI-IL-23 HUMAN ANTIBODIES, COMPOSITIONS, METHODS AND USES
Zheng et al. Fluid shear stress regulates metalloproteinase-1 and 2 in human periodontal ligament cells: involvement of extracellular signal-regulated kinase (ERK) and P38 signaling pathways
BRPI0720361A8 (en) METHOD FOR MEASURING AGGLUTINATION OF ONE OR MORE PARTICLES IN A TARGET-INDUCED AGGLUTINATION ASSAY PERFORMED IN A REACTION CHAMBER, AND, KIT AND DEVICE FOR MEASURING ONE OR MORE PARTICLES AGGLUTINATION ASSAY IN A TARGET-INDUCED AGGLUTINATION ASSAY
BRPI0509419A (en) enzyme-linked immunosorbent assay method, antibodies, hybridoma and immunoassay kit
HRP20100356T1 (en) Diagnostic marker for cancer
Lindquist et al. Influence of surface hardener on gypsum abrasion resistance and water sorption
BRPI1011564A8 (en) SURGICAL SUTURE MATERIAL THREAD, SURGICAL KIT AND METHOD FOR PRODUCING THREAD
BR0016265A (en) Immunoassay for neonicotinic insecticides
CA2798562A1 (en) Methods and compositions for the diagnosis and treatment of thyroid cancer
BRPI0812875A2 (en) "METHOD TO IDENTIFY IF AN INDIVIDUAL IS AT RISK OF SEVERA SEPSIS DEVELOPMENT, SPECIFIC ANTIBODY FOR HEPARIN-BINDING PROTEIN, METHOD TO REDUCE THE RISK OF AN INDIVIDUAL SEVERA," SEVEN SEP.
BRPI0710483A8 (en) compositions and kits useful for the treatment of respiratory diseases
BRPI0814343A2 (en) MATERIALS AND METHODS FOR SPERM SEXING SELECTION
BRPI0505586A (en) antibiotic-containing bone substitute material / delay-acting active substance-releasing antibiotics
BR112015030839A2 (en) artificial nail removal method, artificial nail composition, artificial nail, artificial nail formation method, and nail technique kit
Narita et al. An explanation of the mineralization mechanism in osteoblasts induced by calcium hydroxide
BRPI0505448A (en) conditioning device and its use
EP2437065A3 (en) Biomarker for liver inflammation
BRPI0608149A2 (en) salt of a dopamine agonist, a composition comprising it, use and process for its preparation and intermediate compound
Gitalis et al. Human neutrophils compromise the restoration-tooth interface